{"name":"Aragon Pharmaceuticals","permalink":"aragon-pharmaceuticals","crunchbase_url":"http://www.crunchbase.com/company/aragon-pharmaceuticals","homepage_url":"http://www.aragonpharmaceuticals.com","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"cancer, prostate, therapeutics, discovery-stage, biopharmaceutical, hormone-resistant","alias_list":"","email_address":"info@aragonpharmaceuticals.com","phone_number":"858-369-7600","description":"Hormone-resistant Cancer Treatment","created_at":"Wed Jun 17 21:23:01 UTC 2009","updated_at":"Fri Oct 05 10:10:39 UTC 2012","overview":"<p>Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.</p>","image":{"available_sizes":[[[150,43],"assets/images/resized/0004/9225/49225v2-max-150x150.jpg"],[[226,66],"assets/images/resized/0004/9225/49225v2-max-250x250.jpg"],[[226,66],"assets/images/resized/0004/9225/49225v2-max-450x450.jpg"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"President and Chief Executive Officer","person":{"first_name":"Richard","last_name":"Heyman","permalink":"richard-heyman","image":null}},{"is_past":false,"title":"Chief Medical Officer","person":{"first_name":"Isan","last_name":"Chen","permalink":"isan-chen","image":null}}],"competitions":[],"providerships":[],"total_money_raised":"$122M","funding_rounds":[{"round_code":"a","source_url":"http://onbiovc.com/aragon-pharmaceuticals-inc-series-a-8m/","source_description":"Aragon Pharmaceuticals, Inc.: Series A $8M","raised_amount":8000000,"raised_currency_code":"USD","funded_year":2009,"funded_month":5,"funded_day":27,"investments":[{"company":null,"financial_org":{"name":"The Column Group","permalink":"the-column-group","image":{"available_sizes":[[[150,105],"assets/images/resized/0004/9539/49539v1-max-150x150.png"],[[230,162],"assets/images/resized/0004/9539/49539v1-max-250x250.png"],[[230,162],"assets/images/resized/0004/9539/49539v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"OrbiMed Advisors","permalink":"orbimed-advisors","image":{"available_sizes":[[[150,42],"assets/images/resized/0005/0248/50248v1-max-150x150.png"],[[203,58],"assets/images/resized/0005/0248/50248v1-max-250x250.png"],[[203,58],"assets/images/resized/0005/0248/50248v1-max-450x450.png"]],"attribution":null}},"person":null}]},{"round_code":"b","source_url":"http://www.fiercebiotech.com/story/aragon-pharma-readies-first-cancer-trial-after-22m-b-round/2010-04-22","source_description":"Aragon Pharma readies first cancer trial after $22M B round ","raised_amount":22000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":4,"funded_day":22,"investments":[{"company":null,"financial_org":{"name":"The Column Group","permalink":"the-column-group","image":{"available_sizes":[[[150,105],"assets/images/resized/0004/9539/49539v1-max-150x150.png"],[[230,162],"assets/images/resized/0004/9539/49539v1-max-250x250.png"],[[230,162],"assets/images/resized/0004/9539/49539v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Aisling Capital","permalink":"aisling-capital","image":{"available_sizes":[[[150,56],"assets/images/resized/0004/6625/46625v1-max-150x150.png"],[[159,60],"assets/images/resized/0004/6625/46625v1-max-250x250.png"],[[159,60],"assets/images/resized/0004/6625/46625v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"OrbiMed Advisors","permalink":"orbimed-advisors","image":{"available_sizes":[[[150,42],"assets/images/resized/0005/0248/50248v1-max-150x150.png"],[[203,58],"assets/images/resized/0005/0248/50248v1-max-250x250.png"],[[203,58],"assets/images/resized/0005/0248/50248v1-max-450x450.png"]],"attribution":null}},"person":null}]},{"round_code":"c","source_url":"http://www.xconomy.com/san-diego/2012/03/06/san-diegos-aragon-raises-42-million-targets-hormone-driven-cancers/","source_description":"San Diegoâ€™s Aragon Raises $42 Million, Targets Hormone-Driven Cancers","raised_amount":42000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":3,"funded_day":6,"investments":[{"company":null,"financial_org":{"name":"Topspin Partners","permalink":"topspin-partners","image":{"available_sizes":[[[140,48],"assets/images/resized/0003/0764/30764v1-max-150x150.png"],[[140,48],"assets/images/resized/0003/0764/30764v1-max-250x250.png"],[[140,48],"assets/images/resized/0003/0764/30764v1-max-450x450.png"]],"attribution":null}},"person":null}]},{"round_code":"d","source_url":"http://www.prnewswire.com/news-releases/aragon-pharmaceuticals-raises-50-million-in-series-d-financing-to-advance-promising-therapeutic-candidates-for-hormone-driven-cancers-172635221.html","source_description":"Aragon Pharmaceuticals Raises $50 Million in Series D Financing to Advance Promising Therapeutic Candidates for Hormone-Driven Cancers","raised_amount":50000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":10,"funded_day":4,"investments":[{"company":null,"financial_org":{"name":"venBio","permalink":"venbio","image":{"available_sizes":[[[150,75],"assets/images/resized/0021/4376/214376v1-max-150x150.jpg"],[[232,116],"assets/images/resized/0021/4376/214376v1-max-250x250.jpg"],[[232,116],"assets/images/resized/0021/4376/214376v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Aisling Capital","permalink":"aisling-capital","image":{"available_sizes":[[[150,56],"assets/images/resized/0004/6625/46625v1-max-150x150.png"],[[159,60],"assets/images/resized/0004/6625/46625v1-max-250x250.png"],[[159,60],"assets/images/resized/0004/6625/46625v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"OrbiMed Advisors","permalink":"orbimed-advisors","image":{"available_sizes":[[[150,42],"assets/images/resized/0005/0248/50248v1-max-150x150.png"],[[203,58],"assets/images/resized/0005/0248/50248v1-max-250x250.png"],[[203,58],"assets/images/resized/0005/0248/50248v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"The Column Group","permalink":"the-column-group","image":{"available_sizes":[[[150,105],"assets/images/resized/0004/9539/49539v1-max-150x150.png"],[[230,162],"assets/images/resized/0004/9539/49539v1-max-250x250.png"],[[230,162],"assets/images/resized/0004/9539/49539v1-max-450x450.png"]],"attribution":null}},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"","address2":"","zip_code":"","city":"San Diego","state_code":"CA","country_code":"USA","latitude":null,"longitude":null}],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[{"available_sizes":[[[150,111],"assets/images/resized/0017/7230/177230v1-max-150x150.jpg"],[[250,185],"assets/images/resized/0017/7230/177230v1-max-250x250.jpg"],[[450,334],"assets/images/resized/0017/7230/177230v1-max-450x450.jpg"]],"attribution":null}],"external_links":[]}